The Beauty Health Company (NASDAQ:SKIN) Chairman Brent L. Saunders Acquires 40,450 Shares

The Beauty Health Company (NASDAQ:SKIN) Chairman Brent L. Saunders purchased 40,450 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was bought at an average price of $1.08 per share, with a total value of $43,686.00. Following the acquisition, the chairman now owns 5,921,769 shares in the company, valued at $6,395,510.52. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Beauty Health Stock Down 2.3 %

Beauty Health stock traded down $0.03 during midday trading on Tuesday, hitting $1.26. The stock had a trading volume of 1,355,721 shares, compared to its average volume of 2,212,325. The company has a current ratio of 6.57, a quick ratio of 5.55 and a debt-to-equity ratio of 10.51. The business has a fifty day moving average price of $1.83 and a 200 day moving average price of $2.78. The Beauty Health Company has a 12 month low of $0.91 and a 12 month high of $7.23. The stock has a market cap of $155.77 million, a P/E ratio of -1.84 and a beta of 0.96.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SKIN. Canaccord Genuity Group decreased their target price on shares of Beauty Health from $2.00 to $1.25 and set a “hold” rating for the company in a research note on Monday. Stifel Nicolaus lowered their target price on Beauty Health from $4.00 to $2.00 and set a “hold” rating for the company in a research note on Friday, July 26th. Piper Sandler reiterated an “underweight” rating and issued a $1.00 price target (down previously from $1.50) on shares of Beauty Health in a research note on Friday. TD Cowen reduced their price target on Beauty Health from $4.00 to $3.00 and set a “hold” rating for the company in a report on Monday, May 13th. Finally, DA Davidson restated a “buy” rating and set a $5.00 price objective on shares of Beauty Health in a report on Monday, May 13th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.39.

Institutional Investors Weigh In On Beauty Health

A number of institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in Beauty Health by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 75,281 shares of the company’s stock worth $335,000 after purchasing an additional 5,934 shares during the last quarter. HighMark Wealth Management LLC bought a new position in shares of Beauty Health in the 1st quarter worth about $31,000. Raymond James & Associates acquired a new position in shares of Beauty Health in the 4th quarter valued at about $31,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Beauty Health in the 4th quarter valued at about $31,000. Finally, SG Americas Securities LLC grew its position in shares of Beauty Health by 35.3% during the 4th quarter. SG Americas Securities LLC now owns 39,630 shares of the company’s stock valued at $123,000 after buying an additional 10,332 shares during the last quarter. 93.26% of the stock is currently owned by institutional investors.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.